In a groundbreaking move, Abbott has unveiled its cutting-edge vascular imaging platform featuring the Ultreon 1.0 Software in India. This revolutionary intra-vascular imaging software seamlessly integrates optical coherence tomography (OCT) with the prowess of artificial intelligence (AI), offering physicians an unparalleled view of blood flow dynamics and potential blockages within coronary arteries.
Empowering Precision with Technology:
Abbott's innovative imaging software is a trailblazer, automating the differentiation between calcified and non-calcified blockages. It goes beyond, accurately gauging the severity of calcium-based blockages and measuring vessel diameter. A unique feature lies in its ability to guide precise stent deployment, ensuring optimal stent expansion and apposition. The software delivers instantaneous results, elevating precision during coronary stenting procedures.
Diverging from conventional imaging methods like angiography, Abbott's OCT technology utilizes near-infrared light for high-definition, precise imaging within a blood vessel. This enables physicians to capture intricate details from the most complex patient anatomies. The streamlined workflow of the software facilitates accurate decision-making, minimizing uncertainties and allowing physicians to focus on the paramount task which is providing optimal care to patients and enhancing their quality of life.
Impactful Treatment Decisions:
With the introduction of Ultreon 1.0 Software, Abbott is harnessing OCT technology to assist physicians in making informed treatment decisions. Recent data reveals a remarkable 88% alteration in treatment strategies by physicians dealing with coronary artery blockages. This change is attributed to the invaluable insights provided by OCT when coupled with MLD MAX, a revolutionary workflow guiding stenting decisions and offering physicians strategies to optimize stent placement.
Technology as a Pillar of Healthcare Advancement:
In a market research study commissioned by Abbott titled "Beyond Intervention" in August 2020, physicians and administrators highlighted the pivotal role of technology in improving patient outcomes across the healthcare spectrum. A striking 83.2% of physicians acknowledged that advancements in diagnostic and treatment technologies, such as OCT, have translated into tangible improvements in patient care.
Addressing India's Cardiovascular Challenges:
As cardiovascular diseases cast a growing shadow over India, Abbott remains committed to introducing innovative technologies into the country. The Ultreon Software exemplifies this commitment, providing physicians with advanced tools to deliver the highest level of care and achieve the best possible outcomes for patients.
Tushar Sharma, the general manager for Abbott’s vascular business in India and South Asia, underlines the significance of increased OCT imaging adoption. When combined with AI, it offers cardiologists a more precise and measurable approach to supporting patients undergoing coronary stent procedures.
Abbott's Ultreon 1.0 Software marks a paradigm shift in cardiovascular care, where technology becomes a crucial ally for physicians, guiding them towards more accurate diagnoses, informed treatment decisions, and ultimately, better patient outcomes.